Teva Pharmaceutical shares jump after Goldman upgrades embattled drug-maker, predicts turnaround
December 15, 2017 at 08:04 AM EST
Goldman Sachs raises its rating to buy from neutral for the generic drug maker, citing Teva's aggressive cost cutting targets for the next two years.
